The latest price target for HOOKIPA Pharma (NASDAQ:HOOK) was reported by RBC Capital on December 20, 2024. The analyst firm set a price target for $2.00 expecting HOOK to fall to within 12 months (a possible -6.54% downside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for HOOKIPA Pharma (NASDAQ:HOOK) was provided by RBC Capital, and HOOKIPA Pharma downgraded their sector perform rating.

There is no last upgrade for HOOKIPA Pharma

The last downgrade for HOOKIPA Pharma Inc happened on December 20, 2024 when RBC Capital changed their price target from $48 to $2 for HOOKIPA Pharma Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HOOKIPA Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HOOKIPA Pharma was filed on December 20, 2024 so you should expect the next rating to be made available sometime around December 20, 2025.

While ratings are subjective and will change, the latest HOOKIPA Pharma (HOOK) rating was a downgraded with a price target of $48.00 to $2.00. The current price HOOKIPA Pharma (HOOK) is trading at is $2.14, which is out of the analyst’s predicted range.